Kornimate/medical-research-clean huggingface dataset:
nesiritide therapy to preserve function of the left ventricle after myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (bnp, nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.

post acute myocardial infarction (ami) left ventricular (lv) remodeling begins within hours of the acute event with permanent consequences. previous studies have demonstrated that lv remodeling is one of the major determinants of long-term survival post ami. recent studies have reported that the cardiac natriuretic peptides, atrial natriuretic peptide (anp) and bnp have direct anti-fibrotic and anti-proliferative effects on the myocardium. more importantly, it has been reported that in the acute phase of ami, the secretion of the cardiac natriuretic peptides may be insufficient relative to the chronic phase. therefore, augmentation of the cardiac natriuretic peptide system, such as by exogenous administration of exogenous peptide may prevent post ami lv remodeling because of the cardioprotective effects. the objective of this study is to to determine the efficacy of iv human bnp (nesiritide) as compared to placebo to prevent adverse post ami lv remodeling. this is a randomized double blinded placebo controlled study to determine efficacy of 72 hours of iv bnp at 0.006µg/kg/min as compared to placebo in patients with anterior st-elevation myocardial infarction and successful revascularization. the study population will include 60 patients admitted to the cardiac care unit with a first anterior ami and successful reperfusion therapy (timi grade 3 flow) within 24 hours of onset of chest pain documented by coronary angiography.

Eligibility criteria:
inclusion criteria: * patients with acute st elevation myocardial infarction with \> or = 2 mm st elevation in one or any combination of anterior leads, with successful revascularization (timi grade 3 flow) of the lesion within 24 hours of symptoms and consented within 24 hours of procedure. exclusion criteria: * cardiogenic shock or hypotension, systolic bp\< 90 mmhg or overt congestive heart failure (chf) * previous history of mi (myocardial infarction) * previous ecg suggesting previous mi * known ejection fraction (ef) \< 30% * atrial fibrillation * previously known significant valvular disease (grade iii, iv), cardiomyopathy and congenital heart disease. * hemoglobin \<10 mg/dl * pregnant women/nursing mothers * participants still menstruating and have not been surgically sterilized must have a negative pregnancy test prior to participating in this study. * unable to undergo cardiac mri (magnetic resonance imaging). * contraindications to mri include pacemaker or defibrillator, pregnant women, atrial fibrillation or other arrhythmia, cerebral aneurysm clips or severe claustrophobia.
contrast enhanced ultrasound in human crohn's disease-lumason

Conditions: Crohn Disease

Summary: the investigators plan to compare contrast-enhanced ultrasound to ct and mri for the detection and quantification of intestinal inflammation in the the setting of pediatric small bowel crohns disease

the proposed study will investigate the use of an fda-approved ultrasound microbubble contrast agent (lumason; bracco diagnostics) in pediatric and adult crohn's disease patients undergoing either mr enterography (mre, or mri of the bowel) or ct enterography (cte, or ct of the bowel). in april 2016, lumason was fda approved for intravenous administration and imaging of the liver in children. imaging of the bowel will employ an identical administration method to that described for liver imaging, but the ultrasound transducer will be placed over the affected intestines as opposed to liver.

Eligibility criteria:
inclusion criteria: * histologic evidence of small bowel crohn's disease, or clinical evidence of disease (including radiologic confirmation \[either ct or mri\] and receiving medical therapy for crohn's disease). * between ages 10 and 18 years. * undergoing clinically-indicated cte or mre with evidence of active disease based on pediatric gastroenterologist clinical assessment exclusion criteria: * patients under the age of 10 or over the age of 18. * pregnancy or breast feeding. urine pregnancy testing will be performed on all female study participants of reproductive potential. * obesity/body habitus preventing visualization of small bowel affected by crohn's disease by ultrasound (body mass index ≥30 kg/m2 * subject inability/unwillingness to consent or child assent, including severe developmental delay/mental retardation. * prior allergic-like reaction or other severe adverse event to lumason or any of the active ingredients in lumason (specific contraindication from package insert). * known unstable cardiopulmonary conditions (including any history of acute myocardial infarction/acute coronary artery syndrome, arrhythmia, and congestive heart failure), ongoing acute or chronic kidney disease (egfr \<30 ml/min), moderate/severe chronic lung disease, and end-stage liver disease.
mechanisms of exercise intolerance in heart failure with preserved ejection fraction

Conditions: Heart Failure, Diastolic

Summary: the global objective of this study is to determine the mechanisms of exercise intolerance and dyspnea on exertion (doe) in patients with hfpef and based on this pathophysiology, test whether specific exercise training programs (whole body vs single leg) will result in improved exercise tolerance.

this will be a randomized, non-blinded prospective intervention testing the effects of two types of exercise training, whole body and isolated single leg, on hfpef patients with either central or peripheral limitations to exercise training. subjects will undergo baseline maximal exercise testing and invasive right heart catheterization to define exercise tolerance and pulmonary and cardiac pressures during exercise. based on the results of baseline testing, subjects will be divided into either centrally limited, defined as excessive rise in pulmonary capillary wedge pressure more than 25 mmhg that decreases after administration of sub-lingual nitroglycerin resulting in improved exercise tolerance, or peripherally limited, defined as no improvement in exercise tolerance despite reduction in pulmonary capillary wedge pressure after sublingual nitroglycerin. after baseline testing, subjects will be randomized to either whole body cycle exercise supplemented with sublingual nitroglycerin to improve training responsiveness or isolated single leg exercise training for 4 months. after 4 months, subjects will repeat maximal exercise testing and invasive right heart catheterization to assess responses to 4 months of exercise training.

Eligibility criteria:
inclusion criteria: * signs and symptoms of heart failure * an ejection fraction \> 0.50 * objective evidence of diastolic dysfunction exclusion criteria: * age \< 60 years * bmi \> 50 kg/m2 * pde5 inhibitor use * severe valvular disease * severe copd * ckd 4 or higher * contra-indication to mri.

Keywords: exercise hemodynamics, heart failure
comparison of 3 in vivo microscopic imaging techniques for the diagnosis of pigmented tumors

Conditions: Basal Cell Carcinoma; Lentigo Maligna; Melanoma; Nevus; Seborrheic Keratosis; Lentigo

Summary: reflectance confocal microscopy (rcm) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision. however, it is not widely used due to its high cost and highly technical and time-consuming nature. in addition to reflectance confocal microscopy (rcm), it currently use 2 less expensive dermatoscopes that also allow in vivo diagnosis: super-high magnification dermoscopy (d400) and fluorescence-advanced videodermatoscopy (fav).

several studies have demonstrated their interest in the in vivo diagnosis of melanocytic tumors, but without any comparison between these methods. in our current practice, many patients have benefited from these 3 imaging modalities for benign and malignant lesions. therefore, our aim is to analyze these images and compare their performance in the diagnosis of benign and malignant pigmented lesions.

Eligibility criteria:
inclusion criteria: * patients with a pigmented skin lesion of more than 3mm diameter which have benefited systematically of all 3 imaging techniques at the same time, followed by either a surgical excision or annual imaging monitoring. exclusion criteria: * bad quality images * insufficient number of images * uncertain diagnosis given by the pathologist * refusal

Keywords: melanoma diagnosis diagnosis imaging fluorescence-advanced videodermatoscopy reflectance confocal microscopy super-high magnification dermoscopy
impact of glaucoma and visual field loss on life space

Conditions: Primary Open-angle Glaucoma

Summary: mobility refers to a person's purposeful movement through the environment from one place to another and can be conceptualized as a continuum from bed bound (immobility) on one extreme to making excursions to distant locations on the other extreme. primary open-angle glaucoma (poag) is a chronic, progressive optic neuropathy that can lead to gradual loss of vision in the peripheral field and central vision. older adults with poag have an increased risk for motor vehicle collisions and falls. moreover, existing studies suggest that patients with poag exhibit more postural sway while standing as measured by a balance platform and also tend to walk more slowly than those who are normally sighted and free of ocular disease. while these disturbances likely influence mobility, there has been little research directly assessing the impact of poag on mobility. this study will assess the impact of poag on life space (one aspect of mobility) and will determine whether difficulties with life space are associated with difficulties experienced under conditions of dim lighting.

aim 1: to examine the extent of life space in older adults with poag using the life space questionnaire and to examine whether life space in persons with poag is associated with the magnitude of visual field impairment. aim 2: to examine difficulties seeing under dim illumination and at night in older adults with poag using the low luminance questionnaire and to examine whether greater difficulty in seeing under dim illumination and at night is related to the magnitude of visual field loss. aim 3: to examine the relationship in older adults with poag between visual problems seeing under dim illumination and at night (low luminance questionnaire) and their life space (life space questionnaire).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary open-angle glaucoma * best-corrected visual acuity of 20/40 or better * spherical refraction within ± 5 diopters * cylinder refraction within ± 3 diopters exclusion criteria: * history of intra-ocular surgery other than uncomplicated cataract or glaucoma surgery * significant cognitive impairment
adaptive randomization of aerobic exercise during chemotherapy in colon cancer

Conditions: Colonic Neoplasms

Summary: to goal of this clinical trial is to quantify the dose-response effects of aerobic exercise training compared to attention control on chemotherapy relative dose intensity in colon cancer survivors.


Eligibility criteria:
inclusion criteria: * age ≥18 years * histologically confirmed stage ii or iii colon cancer * completed surgical resection with curative intent * plan to initiate chemotherapy * engage in \<60 minutes per week of moderate- to vigorous-intensity structured aerobic exercise * no planned major surgery during the study period * readiness to exercise, as determined by a modified version of the physical activity readiness questionnaire * can walk 400 meters * can read and speak english * ability to provide written informed consent * provide written approval by qualified healthcare professional * willing to be randomized exclusion criteria: * evidence of metastatic colon cancer * concurrently actively treated other (non-colon) cancer * currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks * currently participating in another study with competing outcomes * any other condition that, in the opinion of the investigator, would preclude participation or successful compliance with the protocol * any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol
biodistribution and dosimetry of ga-68 p16-093 in prostate cancer

Conditions: Prostate Cancer Recurrent; Prostate Cancer

Summary: initial performance of ga-68-p16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in bcr patients, and correlation of ga-68-p16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.


Eligibility criteria:
inclusion criteria (cohort 1): * male ≥ 18 years of age * prostate cancer patients presenting with rising psa after radical prostatectomy for treatment if primary disease. * psa ≥ 0.2 ng/ml * patients must give informed consent for the research study, and agree to allow investigator access to clinical results following treatment plan implementation such as description of the treatment plan and psa values following implementation of treatment plan as part of standard care, typically determined 3-4 months after treatment. inclusion criteria (cohort 2): * male ≥ 18 years of age * histologically confirmed prostate cancer with following gleason scoring at biopsy: * gleason ≥ 4+3 or * gleason 3+4 with \>30% pattern 4 or ≥3 cores positive * scheduled for radical prostatectomy (expected to occur within 60-days of scanning) * patients must give informed consent for the research study, and agree to allow investigator access to the clinical results such as soc imaging (mpmri, e.g.) for surgical planning if done, or biopsy data following prostatectomy including lymph node dissection biopsy data, if available. exclusion criteria (cohorts 1\& 2): * inability to give informed consent. * patient is unable to tolerate remaining still on the bed of the pet camera, due to physical limitations or claustrophobia. * significant acute or chronic medical, neurologic, or illness in the subject that, in the judgment of the clinical investigators, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study
effect of ski sport on physical performance

Conditions: Physical Performance; Pain; Quality of Life

Summary: the aim of the study is to investigate the effect of ski sport on physical performance, pain, and quality of life compared to sedentary individuals of similar age groups and to examine the existence of gender-specific differences.

the aim of the study is to investigate the effects of skiing on physical performance, pain, quality of life, and gender-specific differences. in this context, aerobic/anaerobic performance, body balance, hand-grip strength, and back-leg-chest strength were evaluated in male and female ski athletes and age- and sex-matched sedentary controls. in addition, pain experiences, low back pain-related disability level, and quality of life of all participants were questioned using sf 36, mcgill pain questionnaire (mpq), oswestry low back pain disability questionnaire (olbpdq), and vas scales. the data thus collected were used to determine whether skiing had any effect on physical performance and quality of life, as well as the possible impact of skiing on gender-specific differences.

Eligibility criteria:
inclusion criteria: skiers group; * being an active athlete for at least the last 2 year and affiliated with the national ski federation * international physical activity questionnaire-short form (ipaq-sf) total score above 3000 mets min/week control group; * being healthy and non-athletic with no ski experience * having similar sociodemographic characteristics with skiers group * ipaq-sf total score below 3000 mets min/week exclusion criteria: * history of surgery and/or serious trauma to the spine, lower and upper extremity, * chronic illnesses * substance addiction such as cigarette-alcohol, etc. * during the study; the need of receiving treatment/ interventions due to trauma or any other conditions is concluded with withdrawal from the study

Keywords: skiing gender difference muscle strength physical performance pain quality of life
rct to investigate whether an exercise programme improves the physical performance and qol after bmt

Conditions: Hematological Malignancies

Summary: the hypothesis is that exercise will improve the physical performance and quality of life of bone marrow/ haemopoietic stem cell transplants.the aim of the trial is to provide definite clinical evidence as to which( if any) type of exercise is most beneficial for this patient population. it is also aimed at improving the provision of physiotherapy services to this group of patients.

a three group, single blinded, randomised trial was designed to compare the effects of 1. aerobic plus active exercise and 2. aerobic plus resistance exercise to 3. control group of bone marrow/haemopoietic recipients not recieving exercise. the hypotheses being tested is that 1. exercise improves the physical performance of transplants recipients. 2. exercise improves the quality of life of these patients; 3. resisted exercise added to aerobic exercise increases muscle strength or lean muscle mass and 4. there are no adverse events during either form of exercise

Eligibility criteria:
inclusion criteria: recipient bone marrow transplant alfred hospital, platelets \>= 20 x 10e9 / l provide written consent, 30 days after a bone marrow transplant have an absolute neutrophil count of 1x10e9/l be in a stable medical condition exclusion criteria: febrile neutropenia have active graft versus host disease have cardiomyopathy (ejection fraction \ 28% oxygen

Keywords: hematological malignancies. bone- marrow/ haemopoetic transplant exercise
effect of sildenafil on endothelial function

Conditions: Impotence

Summary: we are investigating the chronic effect of daily assumption of viagra on the blood vessels function in patients with impotence. the study will include 2 groups: 1- patients with multiple risk factors, e.g. hypertension 2- patients with no cardiovascular risk factors

we are investigating the chronic effect of daily assumption of viagra on the blood vessels function in patients with impotence. the study will include 2 groups: 1- patients with multiple risk factors, e.g. hypertension 2- patients with no cardiovascular risk factors

Eligibility criteria:
inclusion criteria: * age 40-70 * impotence * with and without hypertension, hypercholesteremia or dm exclusion criteria: * chf: nyha \> ii * stable angina: ccs \> ii * nitrate treatment

Keywords: impotence endothelial function autonomic nervous system
effect of probiotics (vivomixx®) on weight, microbiota and glucose tolerance in obese pregnant women and their newborn

Conditions: Pregnancy; Obesity; Gestational Diabetes Mellitus

Summary: the purpose of the study is to investigate if the probiotics vivomixx® can affect gestational weight gain, microbiota and pregnancy complications in pregnant obese women and birth weight body composition of their infants.

accumulating evidence indicates that the gut microbiota plays a significant role in obesity and because the "ideal" composition of the gut microbiota remains poorly understood, modulation of the gut microbiota composition represents a potentially attractive treatment option against excessive gestational weight gain and adverse outcomes for obese pregnant women and their newborn. dietary supplements in the form of probiotics could be an efficient treatment for controlling weight gain in pregnancy by inducing changes in the gut microbiota and could have influence on infant's microbiota, which could have important implications for infant development and health. a pilot study including 50 obese pregnant nulliparous with bmi between 30-35 kg/m2 will, after accepting participation, be randomized to receive daily placebo or probiotics (four capsules of vivomixx®; total of 450 billion cfu/day) from gestational age 14-20 until delivery. the infants will be followed until 9 months of age. shortly after birth, tissue composition will be measured in the infants by dexa-scanning. the women will be monitored by weight, blood-, fecal- and urine samples, diet questionnaires and hospital record review. vivomixx® is a probiotic mixture of 8 probiotic strains, (bifidobacterium breve, bifidobacterium longum, bifidobacterium infantis, lactobacillus acidophilus, lactobacillus plantarum, lactobacillus paracasei, lactobacillus bulgaricus and streptococcus thermophilus). this is the first pilot study in which the probiotic vivomixx® are added in a randomized fashion to the standard of care in obese pregnant women. 50 pregnant women are planned to be included. the aim of this group size is to clarify the feasibility, compliance and to estimate parameters such as the standard deviation which will be used in a sample size calculation for a full-scale trial.

Eligibility criteria:
inclusion criteria: * bmi ≥ 30 and ≤35 kg/m2- calculated from pre-pregnancy weight * primiparous singleton pregnancy * able to read and speak danish * normal ultrasound scan of the fetus at gestational age 12-14 * oral glucose tolerance test at gestational age 14-20 exclusion criteria: * pregnancy at \> 20 weeks gestation at recruitment * pre-gestational diabetes or other serious diseases * multiple pregnancy * previous bariatric surgery * ingestion of probiotics \< 1 month before the inclusion or ingestion of other kinds of probiotics than the study probiotics

Keywords: probiotics vivomixx® microbiota